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Abstract
Since the discovery of leukemic stem cells (LSCs) over a decade ago, many of their critical biological
properties have been elucidated, including their distinct replicative properties, cell surface
phenotypes, their increased resistance to chemo-therapeutic drugs and the involvement of growth-
promoting chromosomal translocations. Of particular importance is their ability to transfer
malignancy to non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice.
Furthermore, numerous studies demonstrate that acute myeloid leukemia arises from mutations at
the level of stem cell, and chronic myeloid leukemia is also a stem cell disease. In this review, we
will evaluate the main characteristics of LSCs elucidated in several well-documented leukemias. In
addition, we will discuss points of therapeutic intervention. Promising therapeutic approaches include
the targeting of key signal transduction pathways (for example, PI3K, Rac and Wnt) with small-
molecule inhibitors and specific cell surface molecules (for example, CD33, CD44 and CD123), with
effective cytotoxic antibodies. Also, statins, which are already widely therapeutically used for a
variety of diseases, show potential in targeting LSCs. In addition, drugs that inhibit ATP-binding
cassette transporter proteins are being extensively studied, as they are important in drug resistance
—a frequent characteristic of LSCs. Although the specific targeting of LSCs is a relatively new field,
it is a highly promising battleground that may reveal the Holy Grail of cancer therapy.
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Overview of hematopoietic and leukemic stem cells
Perhaps the Holy Grail in cancer therapy today is the cancer stem cell (CSC) (also known as
the cancer-initiating cell). Tumors possess a minor fraction of CSC, which maintains the
propagation of the disease. In many cancer types, it is difficult to completely eliminate the CSC
and reoccurrence of the cancer usually occurs. In the following review, we will discuss the
leukemic stem cell (LSC) (also known as leukemia-initiating cell). Normal hematopoietic stem
cells (HSCs) were first described by Till and McCulloch in 1961.1 Stem cells can be broadly
defined by their potential for self-renewal and ability to proliferate and differentiate into diverse
cell types. HSCs comprise a very small, but critical, sub-population of the total number of
hematopoietic cells, making up less than 0.01% of cells in the bone marrow.2 An overview of
the HSC and LSC is presented in Figure 1.
In 1994, Dick and co-workers3 disassociated LSCs from the bulk of acute myeloid leukemia
(AML) cells. The immature LSCs resided within the CD34+ CD38- sub-population and were
only a small fraction of the total leukemic blasts. Importantly, LSCs were able to transmit AML
to non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice and repopulate
the bone marrow of the irradiated recipients.4 In contrast, CD34+ CD38+ AML cells were not
competent in engrafting in NOD-SCID mice. NOD-SCID mice were shown to be superior in
comparison with SCID mice for the engraftment of AML and hence continue to be used
extensively to investigate the differences between normal and LSC.5
The study performed in the Dick laboratory, along with similar studies by other investigators,
led to the formulation of the CSC hypothesis, which postulates that tumors are maintained by
a small minority of stem-like cancer cells, which possess the capacity for indefinite self-
renewal. Functionally, CSCs are often defined by their capacity to transfer the malignancy to
NOD-SCID mice. Since this initial discovery, CSCs have been documented in several other
cancers including solid tumors.5 The studies on LSCs and CSCs have revolutionized current
perceptions regarding cancer occurrence and therapeutic options.
Differences between LSCs and leukemia cells
Numerous investigations have provided evidence that AML arises from genetic mutations. It
is not currently known for certain whether the mutations occur in the normal stem cells or in
more differentiated cell types, which then acquire stem cell-like features. In studies by
Morrison and Weissman,6 using lentiviruses, long-term (LT)-LSC and short-term (ST)-LSC
cells was characterized, which have LT and ST repopulating potentials, respectively.
In other studies by Dick et al.,4,7 using clonal tracking by lentiviruses, LT-LSC and ST-LSC
cells was further characterized. LT-LSCs are defined by a long-termed persistence in a
xenotransplant murine model and are characterized by extensive self-renewal capacity,
whereas ST-LSCs possess a reduced self-renewal and show only a transient repopulation
capability. LT-LSCs can give rise to ST-LSCs. Clearly, the definition of LT-LSC and ST-LSC
was derived from their repopulation capability in a murine model, but this hierarchy of LSC
provides a good explanation for the emergence of a primary leukemia and its relapse in humans.
Apart from their repopulation capabilities, AML LSCs in general can been identified by an
aberrant CD expression pattern (see below). Conclusive discriminative parameters between
LT-LSC and ST-LSC apart from of their proliferative characteristics have not been defined so
far.
Some studies suggest that the original target of cellular transformation for the LSC arise from
the HSC compartment.8 However, other studies by Cozzio et al.,9 using lethally irradiated
recipient mice, have demonstrated that the oncogenic MLL-ELL and MLL-GAS7
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chromosomal translocations can transform not only HSCs but also myeloid-restricted
progenitors that lack self-renewal capacity. These MLL-ELL- and MLL-GAS7-transfected
cells have LSC-like properties.9 Other oncogenic chromosomal translocations, such as MLL-
ENL, are able to transform HSCs, but not differentiated progenitors into LSCs.10 This
demonstrates that although the myeloid-restricted progenitor can be a transformation site in
AML, it may not be a frequent site and it may depend on the particular chromosomal
translocation.8 Some translocations such as MLL-ELL also result in an increase in the LSC
pool. A comparison of LSC with leukemia cells is presented in Figure 2.
Regardless of knowing the precise cell type where the original genetic mutation occurred, stem
cells most likely pose both the key and barrier to discovering effective leukemia therapies.
Although stem cells have the potential for self-renewal, they spend the majority of their time
in the G0 phase of the cell cycle. This means that chemotherapeutic drugs, which act on cycling
cell populations, such as 5-fluouracil, are less effective on LSCs than on regular leukemic cells.
11 The quiescent, non-cycling state of LSCs may contribute to their resistance to conventional
chemotherapeutics. Conventional chemotherapeutic drugs that target leukemic cells have been
shown to be ineffective in completely eradicating LSCs. This quiescent nature of LSCs may
result in low rates of long-term remission and multidrug resistance.
LSCs
Leukemias are characterized by the uncontrolled overproduction of leukocytes, which can be
immature or differentiated. Acute leukemias consist of either immature progenitor cells without
lineage differentiation or immature but already lineage-determined cells (for example, acute
promyelocytic leukemia). Chronic leukemias are characterized by mature cells, for example,
chronic myeloid leukemia (CML), which compromise mature granulocytes, and chronic
lymphocytic leukemia (CLL), which comprise terminally differentiated cells. Leukemia can
be further classified on the basis of the origin of malignant leukocytes. Cells of granulocyte,
monocyte, erythroid or megakaryocyte lineage are considered of myeloid origin, whereas B
cells, T cells and natural killer cells are considered of lymphoid origin.5
Although LSCs in AML were the earliest documented and the best characterized, stem cells
exist and have also been discovered in various other leukemias including, CML, acute
lymphoblastic leukemia (ALL) and CLL. Using a variety of techniques, including cytogenetics,
fluorescence in situ hybridization and expression profiling by RNA analysis (reverse
transcriptase-PCR), stem cells from the various leukemias have been isolated and
phenotypically characterized.8 An overview of the phenotypic differences between AML stem
cells and AMLs is presented in Figure 3.
CML and CML-LSC
CML is often characterized by the overproduction of mature myeloid cells. It is further
subdivided into three distinct phases, namely chronic phase (CP), acute phase (AP) and blast
crisis (BC), which is phenotypically similar to AML. Whereas LSCs in AML are biologically
and functionally distinct compared with HSC, LSCs in CML are often phenotypically similar
to normal HSCs. CML stem cells are present in CD34+ CD38- cells and contain the Philadelphia
chromosome. The Philadelphia chromosome contains the chromosomal translocation between
the break point cluster region gene and the gene encoding c-Abl (BCR-ABL). The protein
products of the BCR-ABL chromosomal translocation are p210BCR-ABL and p190BCR-ABL.
Patients with CML have a clonal expansion of hematopoietic cells that express these BCR-
ABL proteins. BCR-ABL expression has been determined to be essential for the sustained
proliferation of leukemic cells in murine models.12 Current treatment of CML uses ABL kinase
inhibitors, and to a much lesser extent chemotherapy, HSC transplantation and interferon-α.
Problems with current therapy include acquired resistance to kinase-inhibitor therapy and a
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lack of sustained molecular remissions.5 An overview of the phenotypic differences between
CML stem cells and CML is presented in Figure 4.
CML stem cells are CD90+, Thy1+ and Lin-. BC-CML patients have higher levels of the
progenitor pool (CD34+ Lin- cells) than other CML patients. CML patients who are responsive
to BCR-ABL-targeted therapy have fewer CD34+ Lin- cells in comparison with patients non-
responsive to BCR-ABL inhibitors. Although the β-catenin pathway is equally activated in
normal vs CML stem cells, this pathway was determined to be overexpressed in patients
resistant to BCR-ABL inhibitors,13,14 and it will be further discussed below. The differences
in response in patients resistant to BCR-ABL kinase inhibitors as compared with those not
resistant imply the acquisition of self-renewal capacity and other selective genetic changes in
granulocyte-macrophage progenitors present in the CML stem cells.13 These results
demonstrate the complex differences between CML stem cells and the bulk of CML cells.
Although both cell types display enhanced proliferative capacity in comparison with normal
myeloid cells, they display different proliferative capacities in the presence of BCR-ABL
inhibitors, which may be due to the presence of discrete additional mutations in the BCR-ABL
gene present in the CML LSC (see below) or selection as a result of treatment.
Some of these CML LSCs display elevated BCR-ABL expression and changes in the
expressions of the cytokines interleukin-3 (IL-3), granulocyte colony-stimulating factor and
the drug transporters ATP-binding cassette-1 (ABC1)/multi-drug resistance-1 (MDR1),
ABCG2 and the transcription factor Oct-1 upon culture with reduced levels of growth factors.
14 Additional studies by Jiang et al.15 demonstrated that more than 70 different BCR-ABL
mutations were present in the progeny of cultured CML LSCs. This group has hypothesized
that CML patients possess LSCs, which have pre-existing BCR-ABL kinase mutations before
the advent of BCR-ABL inhibitor therapy; hence, the patients already have some resistant CML
stem cells. As the CML LSCs proliferate slowly, the patient may initially respond to therapy,
then given time, the CML LSCs that are resistant to BCR-ABL inhibitors emerge (see
mathematical models for CML presented below). This karyotype evolution of resistant cells
from pre-existing CML stem cells, which already have mutations in BCR-ABL, is a lingering
problem in BCR-ABL-directed therapy.15 As CML LSCs, like other LSCs, proliferate slowly,
or are in a quiescent-like state, some investigators have proposed that a means to target these
cells is to stimulate their proliferation and then treat with BCR-ABL inhibitors.16,17 However,
this therapeutic approach will only be appropriate if the CML LSCs do not contain the T315I
BCR-ABL or a similar mutation, which confers resistance to many BCR-ABL inhibitors.
Mathematical modeling provides evidence for CML LSCs
Upon careful mathematical analysis of the incidence data of CML and reappearance of the
disease after the discontinuation of therapy, it has been predicted that there are CML LSC that
are resistant to BCR-ABL inhibitors such as imatinib.18-21 Basically, if one examines the
decrease in BCR-ABL mRNA transcripts upon and during the course of imatinib treatment,
one observes a decrease in a low, constant level of BCR-ABL mRNA transcripts as long as
the drug imatinib is effective; however, if the patient is taken off imatinib therapy, there is a
dramatic and rapid rebound in the level of BCR-ABL mRNA transcripts, which actually may
exceed the initial levels of BCR-ABL mRNA transcripts. These results suggest the existence
of CML LSCs in the CML patients who are not eliminated by the imatinib treatment. In
addition, this model provides a coherent explanation of the biphasic decrease in the BCR-ABL
transcript level upon initial therapy with imatinib. First, imatinib rather quickly eliminates the
terminally differentiated leukemic cells with an average lifespan of around 20 days, which
leads to a rapid decrease in the BCR-ABL transcript levels. After elimination of these cells,
the less-mature leukemic progenitors with an average lifespan of 125 days under imatinib
therapy are responsible for the slower but continued decrease in the BCR-ABL transcripts. The
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immature CML LSCs are not sensitive to imatinib, even expand slowly over time at a slow
rate and are responsible for a rapid rebound of the leukemic burden upon imatinib cessation,
which can exceed the initial level. Furthermore, if there are mutations in the BCR-ABL gene
that confers resistance to imatinib, the emergence of this clone(s) appears and levels of BCR-
ABL mRNA transcripts increase even in the presence of imatinib, again arguing for the
presence of CML LSCs in the CML leukemia patient. The models of Michor et al. also describe
well the higher incidence of mutations in patients who receive therapy at a later stage of the
disease. In these patients, the increased pool of CML-LSCs has a higher stochastic probability
of mutations, which then lead to a rapid expansion of resistant progenitors and treatment failure.
The quiescent nature of CML LSCs may be responsible in part for the failure of imatinib to
result in their elimination. CML LSC may enter a dormant, imatinib-resistant state or in some
cases enter a proliferative imatinib-sensitive state. In addition, CML LSCs express higher level
of the MDR p-glycoprotein (Pgp). It turns out that imatinib is a substrate for Pgp. Mathematical
models, with various growth-related parameters, have been proposed to explain the
asymmetrical stem cell replication; however, the biochemical mechanisms responsible for the
asymmetry of LSC division are not understood. Mutations occurring in the BCR-ABL gene
are commonly thought to occur before disease onset and treatment, thus they are not believed
to be responsible for the quiescence nature of the CML LSC stem cells. The cells with the
mutant BCR-ABL genes may emerge later, towing to the elimination of cells with the wild-
type (WT) BCR-ABL gene upon imatinib treatment. This model implies that the cells with the
mutant BCR-ABL genes may not proliferate as well initially as the cells with the WT BCR-
ABL gene. On the other hand, conflicting data indicate that these mutations may confer a
growth advantage, even without imatinib treatment.22,23 Clearly these models need further
investigation.
Certain genes have been postulated to be involved in asymmetrical stem cell replication (for
example, partner of inscrutable and lethal giant larvae). Further studies are necessary to confirm
the mechanisms by which these and other genes and genetic processes (for example, DNA
methylation) may influence asymmetrical stem cell division, quiescence and dormancy.
ALL LSC
As with CML, ALL can result from the rearrangement of BCR and ABL genes in Ph1+ cells.
In CML, the translocation is thought to occur at the level of pluripotent stem cells, whereas in
ALL the translocation is believed to arise in cells committed to lymphoid differentiation. ALL
patients with this BCR-ABL rearrangement are referred to as Ph1-ALL. As with both CML
and AML, ALL stem cells also display the cell surface phenotype CD34+CD38-. Further
characterization of cell surface phenotypes is ongoing. In ALL, there are currently three
morphological classifications; L1, which consists of small uniform cells; L2, which includes
large varied cells; and L3, which has large, heterogeneous cells with vacuoles. ALL therapy
includes treatment with chemotherapeutic drugs, such as cytarabine or daunorubicin, and bone
marrow transplantation. As with both CML and AML, challenges include multidrug resistance
and relapse.16
CLL LSC
Finally, the last of the true leukemias for which stem cells have been discovered is CLL. CLL
is the most common leukemia in the Western world and is classified as an overproliferation of
B-lymphoid cells (consisting of the majority of CLL cases) or an overproliferation of T-
lymphoid cells. Treatment consists of conventional chemotherapy using drugs such as
fludarabine, stem cell transplantation and immunotherapy using rituximab and alemtuzumab.
As with other leukemias, disease progression often occurs which is resistant to most therapeutic
approaches.5
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HSCs and their microenvironmental niche
HSC quiescence, self-renewal and differentiation are regulated by both intrinsic and extrinsic
mechanisms. Intrinsic mechanisms include those that affect the epigenetic state of HSCs, as it
is controlled by chromatin remodelers such as (PcG) proteins. Extrinsic mechanisms include
those changes in stem cell fate that are dictated by the microenvironment niche.24 The stem
cell niche is an anatomical compartment located within the bone marrow cavity, and is
composed by extracellular matrix molecules, osteoblasts, osteoclasts and stromal fibroblasts.
The interaction of the HSCs with specific microenvironmental elements is a key regulatory
mechanism in maintenance of its self-renewal and differentiation capacities. Moreover, the
stem cell niche has important functions, such as maintenance of stem cell quiescence by
providing proliferative and inhibitory cues and, in some cases, it also provides stimulatory
signals that induce cell growth.
The molecular events that regulate engraftment and mobilization of HSCs and progenitors are
still incompletely defined. Direct physical interaction between HSCs and their niche seems to
be mediated by several membrane molecules such as integrins and cadherins. Integrins such
as very late antigen 4 and 5 (VLA-4 and VLA-5), for example, are efficient activators of the
small GTPase family members Rac-1 and Rac-2. The deletion of both Rac1 and Rac2 murine
alleles leads to a massive egress of HSCs into the blood from the marrow, demonstrating their
importance in the appropriate positioning of HSCs within the bone marrow
microenvironment25,26(see below).
Further support for the view that stem cells need to be physically associated with their bone
marrow microenvironment arises from studies that demonstrated that in the absence of
membrane-bound Kit Ligand (mKL) in the niche, HSCs are not maintained.27,28 Furthermore,
it was demonstrated that matrix metalloproteinase (MMP)-9-mediated cleavage of mKit-L into
soluble Kit-L resulted in the translocation of HSCs from the quiescent endosteal niche towards
vascular-enriched niches favoring differentiation and HSC mobilization into the peripheral
circulation.29 In MMP-9-/- mice, release of soluble Kit and HSC motility are impaired,
resulting in the failure of hematopoietic recovery and increased mortality.
Once localized within the niche, locally secreted cytokines and growth factors can dictate stem
cell fate by initiating specific signal transduction pathways within the HSC. Transforming
growth factor-β, for example, is one of the best characterized negative regulators of HSCs. It
maintains stem cells in a slow cycling or quiescent state partly by blocking the cell surface
expression of cytokine receptors such as c-Kit, Fms-like tyrosine kinase-3 (Flt3), MPL (c-Mpl,
receptor for thrombopoietin) and IL-6 receptor (IL-6R).30
Fibroblast growth factor-1 (FGF-1) produced by stromal cells may also have a role in stem cell
self-renewal and expansion. Upon binding to its receptors, (FGFR1-4) a variety of signal
transduction pathways can be activated, including the MAPK pathway, STATs and PI3K/Akt
pathway.31
In addition, angiopoietin-1 produced by stromal cells enhances the ability of HSCs to become
quiescent through interaction with its tyrosine kinase receptor TIE2.32 The mechanism of cell-
cycle inhibition by TIE2 still remains to be elucidated, but the cyclin-dependent kinase inhibitor
p21Cip1 is critical for the maintenance of HSCs quiescence.33 Interestingly, the gene encoding
p21Cip1 is directly repressed by c-Myc, another key regulator in the stem cell niche.34 Resting
HSCs are characterized by high p21Cip1 levels and an absence of c-Myc expression, whereas
increasing levels of c-Myc activity are reduced p21Cip1 expression and a more active state of
the HSC.35
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Interaction of LSCs with their microenvironment
Whether LSCs also depend on the niche for self-renewal is currently unclear. Although there
are clear differences between normal stem cells and LSCs, there are also striking similarities.
It seems reasonable to assume that many molecular mechanisms that enable self-renewal are
shared among normal stem cells and LSCs.
Indeed, both normal stem cells and leukemic HSCs depend on stromal cell-derived factor-1
(SDF-1)-mediated CXCR4 (CXC chemokine receptor-4 which is specific for SDF-1) signaling
for homing and mobilization.36 Wnt-induced β-catenin signaling has been implicated in the
maintenance and the expansion of murine HSCs, whereas inhibition of the β-catenin pathway
severely impaired the self-renewal capacity of progenitors in CML.37-39 The adhesion of
normal CD34+ stem/progenitor cells to bone marrow stroma and fibronectin is mediated by
the integrins VLA-4 and VLA-5, and a similar role is fulfilled by integrins in leukemic cells.
40-41 Thus, many of the molecules that mediate the interaction between stem cells and bone
marrow niche are utilized by both normal stem cells and LSCs.
Whether the leukemic cell needs collaborative genetic hits to improve their interactions with
the extrinsic stem cell niche remains an open question. One possibility is that LSCs have much
more active migration machinery when compared with normal HSCs that allow them to escape
growth inhibition or quiescence-promoting signals induced by osteoblasts and stromal cells in
the niche. A number of membrane-associated ligands are normally present in the niche, and it
has been shown that they can be cleaved by MMPs. MMPs and their tissue inhibitors (TIMPs)
were demonstrated to have important implications in the progression and invasiveness of many
malignant disorders. In contrast, the biological significance of these molecules in human
leukemias is not clear. The expression levels of MMPs such as MMP9 are often elevated in
AML blasts.42 It is tempting to speculate that MMPs might increase soluble concentrations of
activate ligands to enable leukemic self-renewal or expansion outside the niche. Therefore, the
level of marrow MMP-9 may be a useful surrogate marker for monitoring disease status in
AML and it was proposed as a potential prognostic factor. Targeted inhibition of MMPs may
inhibit LSCs expansion and may prove useful in leukemia therapy.
Using human AML and mouse CML model, it was recently shown that targeting CD44 with
a monoclonal antibody (MoAb) could suppress both AML and CML progression and induce
differentiation.43-45 The monoclonal anti-CD44 antibody may disrupt interactions between
the LSCs and the bone marrow niche. Rac inhibitors may also disrupt these interactions and
mobilize LSC (see below).
Importance of the Wnt/β-catenin signaling pathway in LSC
The Wnt signaling pathway plays a critical role in self-renewal of HSCs and its dysregulation
may be involved in LSC. There are approximately 20 Wnt genes in the human genome and
they encode lipid-modified secreted glycoproteins.46 Wnt induces cell signaling to a receptor
complex consisting of a Frizzled family receptor and a co-receptor of the LDL receptor-related
protein family, usually LRP5 or LRP6. This can result in the destabilization of the multiprotein
destruction complex (MDC) and the subsequent stabilization of β-catenin. β-catenin normally
has a very short half-life. In the absence of Wnt, β-catenin is normally phosphorylated by
components of the MDC, including axin, adenomatous polyposis coli, glycogen synthase
kinase 3β (GSK-3β) and Casein kinase 1 (CK1). When β-catenin is phosphorylated by these
kinases, it is targeted for proteasomal degradation.
In contrast, if cytoplasmic β-catenin is stabilized by Wnt signaling (that is not phosphorylated
by the MDC complex), it migrates to the nucleus and replaces the Groucho-related repressors
(Grg) present on certain genes. β-catenin in the presence of the accessory proteins Bcl-9, PYGO
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(pygopus) and the TCF/LEF (T-cell factor/lymphocyte enhancer-binding factor) forms a
complex that results in the transcription of important growth-promoting genes, such as c-Myc
and cyclin D1. Furthermore, TCF/LEF can result in an increase in SALL-4 expression
expression, which is an oncogene that can bind to β-catenin and enhance its activity.
Plakoglobin is another important component of Wnt signaling. It is a co-activation of TCF/
LEF transcription activation and stimulates the transcription of cyclin D, c-Myc and perxosome
proliferator-activated receptor-delta (PPARδ). Plakoglobulin expression is enhanced by certain
AML fusion proteins. The Wnt pathway is frequently dysregulated in AML.47 An overview
of the Wnt signaling pathway and its dysregulation in leukemia is presented in Figure 5.
The Wnt pathway is regulated by many different inhibitors, which have been shown to have
important roles in oncogenesis. These interactions are well described in the above-mentioned
outstanding review by Mikesch et al.46 Some key inhibitors include members of the Dickkopf
(DKK) family, which interact with LRP5/6 and prevent the transmission of signals from the
Frizzled-LRP complex. The Wnt inhibitor factor 1 (Wif-1) is another inhibitor of the Wnt
pathway. It is an extracellular protein that binds to Wnt, thereby inhibiting the Wnt pathways.
48 The promoter regions of Wif-1 is hypermethylated in many acute promyelocytic leukemias
and associated with a poorer disease-free 3-year survival rate than in patients without Wif-1
promoter methylation.49
Importantly, this pathway has been shown to have critical roles in self-renewal of HSC and
LSC.37,50 Wnt expression inhibits the differentiation of HCS.51,52 Overexpression of axin,
a component of the MDC, inhibits Wnt signaling and in turn this results in decreased growth
of HSC.37 Constitutive overexpression of activated β-catenin increased the frequency of HSC
and prevented their differentiation.37
In a recent study, which examined the role of specific deletion of β-catenin in hematopoietic
lineages, it was determined that although deletion of β-catenin did not prevent the formation
of HSC, the HSC were deficient in long-term growth and maintenance.50 Furthermore in these
mice, the target(s) for CML LSC and BCR-ABL transformation were greatly reduced while
the induction of ALL occurred fairly normally. These and other results suggest that ALL may
arise from a more mature stem cell committed to the B-cell lineage. Conditional deletion of
β-catenin decreased the self-renewal ability of CML LSC. The authors concluded that β-catenin
is critically needed for the increased self-renewal capacity conferred by the introduced BCR-
ABL oncogene on the target stem cells to permit transformation to proceed along the myeloid
lineage. The authors demonstrated that BCR-ABL phosphorylation was decreased in the β-
catenin-deficient mice, which also resulted in lower levels of phosphorylated STAT5a. Studies
by this group and others53 have demonstrated that BCR-ABL and β-catenin form a complex
and the authors have suggested that this complex may stabilize BCR-ABL. Reduction of the
BCR-ABL/β-catenin complex could result in a decrease in the phosphorylation of BCR-ABL
targets such as STAT5a and also decrease CML self-renewal and disease progression. These
intriguing results provide further evidence of the role of β-catenin and the Wnt pathway in
normal HSC as well as CML LSC and demonstrate the stem cell origin of CML but not ALL.
Wnt signaling may be critical for BCR-ABL stability and the maintenance of CML LSC. The
Wnt pathway may serve to differentiate CML and ALL. The successful development of Wnt
inhibitors may serve to augment the ability of BCR-ABL inhibitors to eradicate CML.
Not unexpectedly, the Wnt signaling pathway interacts with other signaling pathways,
including Notch, sonic hedgehog and PI3K/Akt.54-56 Increased Flt-3 signaling in AML
patients with mutations/amplifications of Flt-3 may result from Akt-mediated phosphorylation
and inactivation of GSK-3β, which results in higher levels of Wnt signaling and stabilized β-
catenin.57 Alternatively, Frizzled-4, a Wnt receptor, is induced by certain Flt-3 mutations,
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which leads to increased β-catenin levels that result in augmented TCF/LEF activity and c-
Myc transcription.58,59
Interactions of BCR-ABL with downstream signaling pathways leading to
imatinib resistance and potential novel targets for therapy
BCR-ABL induces many different signaling pathways, that is, probably an important reason
as to why it is such a ‘potent’ oncogene. BCR-ABL induces the Ras/Raf/MEK/ERK, PI3K/
Akt, p38MAPK, JNK, FAK, Src and Rac signaling cascades.60 BCR-ABL can also interact
with Src-family kinase Hck, which results in Stat5a activation independent of Jak kinases. This
may be an important factor in the resistance of cells to imatinib therapy (see below for section
on Src kinases). Recent data indicate that an important signaling family induced by BCR-ABL
is the Rac family of GTPases, which has been summarized excellently in a recent review
published in Leukemia.60 Rac is a multigene family, which consists of Rac-1, Rac-2 and Rac-3.
Rac-1 and Rac-3 are ubiquitously expressed, whereas Rac-2 is expressed predominately in
hematopoietic cells. BCR-ABL also interacts with Rho GTPases, including Rac, Rho and
Cdc42. Rac-1, Rac-2 and, to a lesser extent, Rac-3 are detected at hyperactivated levels in
HSCs and LSC CMLs. Rac-1 and Rac-2 cooperate with BCR-ABL and induce a
myeloproliferative disease of HSC origin. By the use of Rac-1- and Rac-2-deficient mice,25,
26 it has been determined that the deficiency of Rac-1 and Rac-2 reduces the severity of BCR-
ABL-mediated transformation in animal models, and prolonged survival was observed. Rac-3
is believed to play an important role in the cancer development in the BCR-ABL Rac-1/Rac-2-
deficient mice. These results suggest an important role for Rac GTPase in BCR-ABL-mediated
CML as well as in normal HSC functions. The Rac GTPases and Ras may be important in the
induction of STAT5 which may be abnormally activated by various mechanisms, including an
autocrine mechanism in imatinib-resistant CML.61
Rac proteins have been shown to play key roles in the retention of murine HSC and may be an
appropriate target to eliminate LSC.26,62 The effects of an experimental Rac inhibitor
(NSC23766) on HSC mobilization has been recently examined.26 This inhibitor increased
HSC mobilization, suppressed Rac activation and downstream p21-activated protein kinase
(PAK) activation. NSC23766 also inhibited the growth of BCR-ABL-transformed cells, even
those with the imatinib-resistant T315I mutation.63 This Rac inhibitor may mobilize CML
LSC cells from their niche, and thus inhibit the stem cell properties of these cells. Hence, this
inhibitor, unlike others such as imatinib, may effectively target the LSC.
Role of Src kinases in CML and ALL LSCs
Imatinib has proven highly effective in the treatment of CML; however, it has been shown that
imatinib, by itself, will not cure CML. This is often due to the development of resistance. Src
and other signaling pathways are involved in resistance to imatinib.64,65 Src family kinases
are activated by BCR-ABL, and the inhibition of BCR-ABL by imatinib may not result in the
complete inhibition of Src family kinases. BCR-ABL is known to activate at least three Src
family kinases (LYN, HCK and FGR), which are required for the development of BCR-ABL-
mediated proliferation of pre-B-ALL, but not of myeloid progenitor cells.66 However, all three
of the above-mentioned Src family kinases are activated by BCR-ABL in myeloid cells. BCR-
ABL may directly interact with at least two Src family kinases (LYN and HCK), which may
alter their activities.67,68 By performing elegant genetic studies, it was demonstrated that
LYN, HCK and FYN are required by BCR-ABL to induce CML to lymphoid blast crisis in
mice injected with BCR-ABL-transduced bone marrow.64
As stated previously in this review, some BCR-ABL mutations such as T315I are resistant to
imatinib, dasatinib and other BCR-ABL inhibitors. However, in the studies by Hu et al.,64
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they demonstrated that although BCR-ABL kinase inhibitors prolong the survival of CML
mice, they do not completely eliminate CML LSCs. In these studies, the structures of the BCR-
ABL genes in CML LSC were determined and they did not have the T315I mutation. These
results strongly indicate that other mutations, potentially induced by BCR-ABL, are involved
in CML development and that imatinib and dasatinib are not adequate to completely eliminate
the CML LSC.
Alternatively, other genetic mutations occurring in blast crisis CML may contribute to the
persistent activation of Src. Mutations at other genes, including INK4a, pRb and p53 among
others, are involved in CML progression.69-71 Loss of the Arf gene enhance tumorigenicity
of BCR-ABL-transformed cells and limit the response to imatinib in BCR-ABL-induced B-
ALL mice.72 Studies by Hu et al.,64 have demonstrated that the progression to lymphoid blast
crisis requires activation of Src family kinases and the Src kinase inhibitor dasatinib was more
effective than imatinib in preventing B-ALL; however, eventually the disease reoccurred.
Furthermore, although dasatinib treatment prolonged the life of the CML mice, it did not
eradicate CML stem cells. The authors have therefore suggested that an additional component
of BCR-ABL-expressing CML LSC must be suppressed for complete eradication of the
disease. Furthermore, certain BCR-ABL mutations such as T315I are resistant to imatinib,
dasatinib and other BCR-ABL inhibitors. Interesting, Aurora kinase inhibitors (VX-680) have
shown promise in inhibiting cells imatinib-resistant BCR-ABL, T315I-transformed cells.
73-74
Src kinases may induce the Wnt/β-catenin and Raf/MEK/ERK signaling pathways, which
result in LEF/TCF activation.75-76 Activation of these and other signaling pathways may
contribute to the survival of B-ALL LSC.
Targeting the LSC based on differential receptor expression
For the remaining of this review, unless otherwise stated, we will focus on HSC and LSCs in
the context of AML, as AML stem cells has been the most extensively studied of all the LSCs.
AML, as the name describes is characterized by the overproliferation of immature myeloid
cells. AML is further subdivided into eight morphological classes from M0-undifferentiated
to M7-megakaryoblastic. Current treatment of AML includes FLT-3 kinase inhibitors, HSC
transplantation and chemotherapeutic drugs, such as daunorubicin and others. Unfortunately,
multidrug resistance during therapy and relapse often occurs.5
Although both HSC and LSC are found within the immature CD34+ CD38- fraction of normal
and AML cells respectively, there are distinct markers that separate these two cell groups. The
majority of studies have shown that unlike normal HSCs, AML LSCs usually lack the
expressions of Thy-1 (CD90) and c-Kit (CD117), CD71 and HLA-DR.77 Furthermore, AML
LSCs express IL-3R-α(CD123), CD33, the antigen C-type lectin-like molecule-1 (CLL-1) and
CD96. CD33 is expressed on the cell surface of some normal HSCs, but CLL-1 is detected
exclusively on malignant CD34+ CD38- cells. Surprisingly, activation of the MAPK, Akt and
STAT5 pathways was not detected in response to IL-3 stimulation in some AML LSCs.78
These results may indicate AML LSCs are hyporesponsive to cytokines, which may contribute
to their quiescent nature.
Cytotoxic antibodies can be used as a form of AML therapy. As with other therapies, the ideal
treatment would target LSCs but not affect normal HSC. The CD33+ protein provides one
possible target of intervention. The α-CD33 MoAb conjugated with the cytotoxic antibiotic
calicheamicin induces remission in some cases of AML.79 Part of the effectiveness of this
approach may be a result of the direct killing of CD33+ LSCs, as this drug has been found to
be effective even in patients where the majority of the AML cells are CD33-. In the long-term,
patients on this drug have developed prolonged cytopenia, which may be due to its adverse
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effects on normal HSCs, which are CD33+.80 Nonetheless, the calicheamicin-conjugated α-
CD33 MoAb shows potential as a means of eradicating LSCs before autologous stem-cell
harvest and transplantation.5 An overview of potential targets in LSC therapy based on
differences in gene expression is presented in Figure 6.
CD123, a receptor for IL-3, is also a potential target, as αIL-3R antibodies conjugated to
ozogamicin selectively target AML LSCs in comparison with normal HSC in vitro.81 The
αIL3R-ozogamicin immunoconjugate was further shown to decrease the effectiveness of AML
engraftment in NOD-SCID mice and was hence indicative of its effect on LSCs.79 In addition,
CLL-1 is expressed preferentially on most AML LSCs and is normally expressed on CD38+
myeloid progenitors but not on CD34+ CD38- cells. This makes CLL-1 a selective target in
AML therapy.82
Another cell-surface target on LSCs is CD44. CD44 is overexpressed on both AML and CML
LSCs relative to normal HSC. Using α-CD44 MoAbs, terminal differentiation and apoptosis
of AML cells were observed in engrafted mice.45 The α-CD44 MoAb also reduced the
leukemic burden and abolished the need for secondary transplantation of leukemia. In similar
studies, CD44 has been found to be required for homing and the engraftment of CML LSCs
in mice. CD44 is required for BCR-ABL-expressing cells to induce CML-like disease in mice.
In contrast, CD44 was not required for the engraftment of normal HSCs or B-cell ALL in mice.
45
Targeting the LSC based on altered drug transporter expression
Targeting cell surface proteins has and continues to be one approach to selectively treat and
eradicate LSCs, and hence improve leukemia therapy. Another method to treat these cancers
is to circumvent the problem of drug resistance, which is currently encountered after
conventional chemotherapic drug treatment. Cells develop drug resistance through a variety
of mechanisms that include decreased drug uptake, increased drug efflux, accelerated
detoxification, defective apoptosis or altered expression of signaling pathways.83 ATP-
dependent drug efflux has been linked to the increased expression of ABC transporter proteins.
84
Within the ABC family of active transporters, there are currently approximately 49 separate
transmembrane proteins.84 These transporters are expressed in almost all cells and play
important roles in normal physiology by transporting a variety of nutrients and biologically
active substances across cellular barriers. This family is divided into seven subfamilies, ABCA
through ABCG. Several of these genes, including ABCG1 and ABCB1, are expressed in
immature CD34+ CD38- sub-populations and are downregulated upon differentiation into the
CD34+CD38+ sub-population. Studies by de Grouw et al.85 have demonstrated that 22 ABC
transporters were differentially expressed in AML LSCs versus AMLs, and all were expressed
lower in CD34+CD38+ cells in comparison with the CD34+ CD38- cells. Of these sub-
populations, ABCB1, ABCG2 and ABCC1 are the three primary multidrug-resistant genes
that have been detected to be expressed most frequently in tumor cells. Included in this
subgroup are MDR1, BCRP (breast cancer resistance protein) and multidrug resistance
association protein (MRP1).84 The proteins involved in drug transport have been well
documented to confer drug resistance by mediating the active efflux of many anticancer drugs.
5
MDR1 overexpression specifically often causes resistance to amphipathic drugs such as
paclitaxel and anthracyclines.86 In addition, its expression is higher in patients with secondary
leukemias as compared with those in primary disease states.87 In response, several drugs have
been examined that block and compete with the Pgp (MDR1)-mediated drug efflux.
Unfortunately, the treatment options with the current MDR1 inhibitors have thus far been
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ineffective.84-88 Second-generation MDR modulators have yielded similar results.89 This
may result from MDR1 not being the unique transporter, the cell uses against chemotherapeutic
drugs and suggests that additional agents that inhibit multiple transporter and other modes of
drug resistance would be more effective. Upon examination of the expression of various ABC
transporters, a high redundancy was observed in both normal and early AML cells.85 These
results suggest that current MDR modulators may be ineffective due to the presence of multiple
transporters, which can efflux the same drug, thus making targeting of a single transporter
ineffective. In addition, it is possible that irrelevant transporters were inhibited or there were
pharmacokinetic interactions between the chemotherapeutic agent and the ABC transporter
inhibitor. Third-generation MDR modulators that are more powerful are currently being
developed and examined in clinical settings.84
This ability to efflux many drugs has been practically exploited in the isolation of LSCs. Many
ABC transporters expressed in stems cells efflux the fluorescent dyes Hoechst-33342 and
rhodamine 123. This is in contrast to non-stem cells, which retain the dyes. After
Hoechst-33342 staining and flow cytometric analysis, a large percentage of LSCs have been
shown to reside in the side population cells. In addition, these side population cells are found
in the bone marrow of over 80% of AML patients.84
Targeting the LSC by altered cholesterol metabolism
In addition to multidrug resistance, altered cholesterol metabolism is observed in some AML
patients. This is based on research performed by several laboratories, which shows that AML
cells do not exhibit efficient feedback repression of cholesterol synthesis and low-density
lipoprotein-receptor expression when exposed to high sterol media in comparison with normal
cells.90 This defect in cholesterol metabolism is associated with increased cell survival. This
abnormality was detected by differential gene expression (for example, genes involved in
cholesterol metabolism) in the CD34+ CD38- sub-population of AML cells, which protects
these cells via this pathway. As ABC transporters promote cholesterol efflux, they are also
important in cellular cholesterol homeostasis.84
Cholesterol efflux from cells is induced in part by the activation of liver X receptors. The
activation of liver X receptors enhances the transcription of genes such as ABCA1 and ABCG1.
The functions of these genes are not yet fully defined in hematopoietic cells. However, these
transporters are highly expressed in immature CD34+ CD38- populations and downregulated
upon differentiation. One pivotal study has shown that 58% of AMLs showed an acute
cholesterol response to cytotoxic drugs. This response was not found in normal CD34+ cells
and contributed to AML cell survival. Upon blocking this response, the AML cells showed an
increase in chemosensitivity.91 This provides a rationale for the use of statins to inhibit such
responses. As statins are already widely prescribed, their general effects are well studied and
they are known to be well tolerated.92
In addition, recent reports connect central diabetes insipidus with AML. This association is
believed to be linked to chromosomal abnormalities in the region 3q21q26, a commonality of
the two diseases. Patients with central diabetes insipidus, and specifically the chromosomal
abnormality associated with it, often have a poorer prognosis than non-diabetic AML patients.
93 A common associated problem that diabetics have is increased levels of high-density lipids
and elevated cholesterol levels. These patients often are treated with statins. It is not known
whether the treatment of diabetic patients with statins precludes the AML development.
Furthermore, statins are of great interest because they may result in apoptosis limited to tumor
cells, while not affecting the nontransformed hematopoietic cells.94 Stirewalt et al.92 have
demonstrate that the co-administration of mevastatin with cytotoxic drugs resulted in reduced
leukemic survival. Although the exact mechanisms regarding statin-induced apoptosis are still
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being elucidated, several studies point to the dysregulation of cell signaling pathways.95,96
Specifically, Wu et al.96 demonstrated that lovastatin downregulates constitutive ERK1/2
phosphorylation in AML cells. These data are interesting because in general, the tumor types
that have responded well to statins are the ones associated with constitutive activation of the
Raf/MEK/ERK pathway, which we discuss further in this review. It is important to note that
this same group has demonstrated that lovastatin does not trigger apoptosis solely through the
Raf/MEK/ERK cascade alone and the exact mechanisms continue to be studied.96 Finally,
early phase I clinical trials have shown that high doses of statins are not well tolerated because
of doselimiting toxicities.97 However, in vitro studies demonstrated that when statins were
combined with inhibitors of the Raf/MEK/ERK pathway, such as the MEK1 inhibitor
PD98059, low levels of statins achieved effective if not stronger pro-apoptotic effects.96
LSCs may also express elevated aldehyde dehydrogenase activity.98 Aldehyde dehydrogenase
activity is used to define HSCs but its role in AML LSC is not well elucidated. Recent studies
have indicated that some leukemic AML stem cells express elevated aldehyde dehydrogenase,
which is associated with a poor prognosis.98 The targeting of aldehyde dehydrogenase is
complicated as it most likely plays important functions in many different tissue types, not just
in LSCs.
Targeting the LSC by signal transduction, transcription factor and apoptotic
pathways
Another approach to eliminating LSCs is to determine the pathways that are aberrantly
expressed and identify drugs, which selectively target LSCs while leaving normal HSCs alone,
hence reducing toxicity. Although much remains to be elucidated about the regulation of HSCs
and LSCs, several genes are recognized as being important in the regulation of HSCs. These
include HoxB4 and HoxA9, which have both been implicated in the expansion of hematopoietic
cells both in vivo and in vitro.99,100
The Bmi-1 protein, which is necessary for the self-renewal of HSCs, also has potential as a
target of therapeutic intervention. Bmi-1 is a member of the Polycomb Group (PcG) gene family
and its expression is limited to immature HSC and the CD34+fraction of AML patients.99,
100 Studies with Bmi-1-knockout mice have shown its requirement in blood cell development
by demonstrating the progressive loss of all hematopoietic lineages. When Bmi-1-/- cells were
transplanted into lethally irradiated normal mice, the cells were able to partially reconstitute
myeloid cells and lymphocytes. They did not persist for a prolonged time, as they were unable
to self-renew.99,100
To understand the reason behind this effect, Park et al.100 compared the gene expression
profiles of Bmi-1-/- HSCs with normal HSCs. Bmi-1-/- HSCs have increased levels of cell cycle
inhibitors, such as p16INK4α, p19ARF and p53. p53 induced Wig1 and downregulated apoptosis
inhibitors such as AI-6. The research further supports the theory that cancer is essentially a
disease of stem cells. In addition, the PcG genes have long been suspected of being involved
in oncogenesis and the study performed with Bmi-1 knockout mice further adds support for
this hypothesis. Finally, these studies demonstrate the critical importance of Bmi-1 in stem cell
self-renewal and point to a potential target of intervention that can be used to combat a variety
of cancers.99
As stated earlier, the Wnt signaling pathway may be elevated in LSCs.50 This may arise from
mutations in FLT-3 and chimeric transcription factors, such as promyelocytic leukemia-
retinoic acid receptor-α t(15;17) (PML-RARα) and acute myeloid leukemia-1 gene (8;21)
(AML-ETO). FLT-3 is mutated in over 30% of cases of AML and associated with poor
prognosis and increased relapse rates.101 Internal tandem duplications of the FLT-3 gene have
Misaghian et al. Page 13
Leukemia. Author manuscript; available in PMC 2009 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
been detected in AML LSC.83,101 An end result of these mutations is increased expression
of the Wnt signaling pathway, which may result in increased growth of the LSC. In addition,
cells stimulated with the Wnt ligand are known to stabilize β-catenin. β-Catenin then
translocates to the nucleus and activates specific gene transcription. Overexpression of mutant
β-catenin induces the expansion of HSC.5 For these reasons, targeting of various components
in these pathways (for example, FLT-3) may inhibit LSC growth. Indeed the FLT-3 inhibitor
CEP-701 suppressed the engraftment of FLT-3/ITD LSC.83,101
In addition, the Notch pathway may be deregulated in LSC. Genomic analysis from AML stem
cells determined that the Jagged-2 gene, a Notch ligand is overexpressed in LSC. Inhibition of
γ-secretase by N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT)
inhibits LSC growth. γ-secretase is necessary for Jagged and Notch signaling.102 Likewise,
this group also determined that certain genes are detected at lower levels in LSCs, including
genes involved in DNA repair, signal transduction and cell cycle progression, which is
consistent with the quiescent nature of LSC.
The Wilms' tumor (WT1) gene has also been observed to be expressed at elevated levels in
LSCs.103 WT1 was not expressed at high levels in normal long-term HSCs or in multipotent
progenitor cells. In contrast, in AML1-ETO+TEL-PDGFRbR or BCR-ABL murine leukemias,
WT1 was expressed in approximately 50% of the transplantable LSC.99 Hence, the WT1
protein may be a target for the successful treatment of LSCs.
Transcription factors have been implicated in regulating the LSC. Meis1 has recently been
shown to be an essential and ratelimiting regulator of MLL LSC potential.104 Furthermore,
Wong et al.,105,106 demonstrated that Meis plays a major function in establishing LSC
potential by regulating self-renewal, differentiation arrest and cycling. In contrast, other
transcription factors (for example, PU.1 and JunB) may display reduced expression in AML
stem cells. Although targeting of transcription factors has proven problematic, it is an area with
great potential.
The PI3K/PTEN (phosphatase and TENsin homolog deleted on chromosome 10)/Akt/
mammalian target of rapamycin (mTOR) is another cell signaling pathway of immense
importance with regard to a variety of cancers. This pathway has been determined to be
consistently activated in AML cell lines and strongly contributes to the proliferation, survival
and drug resistance.107 In addition, its upregulation has been specifically observed in LSCs
transplanted in NOD-SCID mice and shown to provide an anti-apoptotic response.108
Although this upregulation is associated with increased drug resistance and a poor prognosis,
a surprising new study by Tamburini et al.109 demonstrated the upregulation of this pathway
is actually a favorable factor in de novo cases of AML. This is perhaps because the upregulation
of this pathway moves immature leukemic cells, including LSCs, into S phase and therefore
makes them more susceptible to certain chemotherapeutic agents, especially those targeting
actively replicating cells.110 An overview of the potential for targeting signal pathways in
LSCs is present in Figure 7.
The PI3K/PTEN/Akt/mTOR pathway is of critical importance because of its effects on
downstream proteins, including Bad, nuclear factor-kappa B (NF-κB) and MDM2. Inhibitors
for several of these proteins, such as NF-κB and MDM2, have been developed and their
efficacies in treating various leukemias and myelomas are being evaluated.111 Although its
specific role remains unclear, the NF-κB transcription factor is of particular interest because
it is found to be particularly active in LSCs but not in HSCs, making it a point of selective
intervention. Proteasome inhibitors, such as salinosporamide A and bortezomib, are currently
being examined in phase I/II trials and show potential.5
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Furthermore, inhibitors of mTOR show promise in LSC therapy. These inhibitors used in
conjunction with conventional therapies induce apoptosis and specifically have been shown to
reduce the abundance of LSCs.5 Upstream of Akt, there also exists the tumor suppressor PTEN,
which has been a further point of intervention, as it is frequently mutated or silenced in human
cancer, including leukemia.112
In addition, recent evidence indicates a relationship between the PI3K/PTEN/Akt/mTOR
pathway and expression of the MRP1, another ABC transporter protein that is also linked with
multidrug resistance. Upregulation of this pathway was found to increase levels of the MRP1
protein.113 These data suggest a p53-dependant mechanism of MRP1, as the inhibition of
MRP1 was linked with a concurrent increase in p53 levels. Inhibition of the ubiquitous ligase,
MDM-2, with Nutlin-3a increases p53 stability and promotes apoptosis of leukemia, which
are WT at p53.114-126 p53 has been shown to be an important target in leukemia. In addition,
the connection between MRP1 and this pathway shows another possible reason for multidrug
resistance in leukemias.
This connection between multidrug resistance and the PI3K/PTEN/mTOR/Akt pathway also
shows the potential of targeting this cascade. Studies using inhibitors to PI3K, such as
Wortmannin and LY294002 in combination with conventional chemotherapeutic drugs,
demonstrated an increased sensitivity of the cells to more readily undergo apoptosis.125,126
Furthermore, as normal hematopoietic progenitors are less affected by these inhibitors, the
potential to selectively target LSCs and AML cells and reduce toxicity is a possibility.110,111
Targeting leukemia stem cells by inhibition the PI3K pathway: importance of
PTEN
Recent advances have highlighted extensive phenotypic and functional similarities between
normal stem cells and CSCs. This raises the question of whether disease therapies can be
developed to eliminate CSCs without eliminating normal stem cells.
Components of the PI3K pathway, including PTEN, Akt and mTOR, are critical regulators of
both normal stem cell function and tumorigenesis. Intriguingly, inactivation of some pathway
components, such as PTEN, has opposite effects on normal HSCs and leukemia-initiating cells.
Therefore, mechanistic differences between normal stem cells and CSCs can thus be targeted
to deplete CSCs without damaging normal stem cells.
PTEN functions as a negative regulator of the PI3K pathway, which has crucial roles in cell
proliferation, survival, differentiation and migration. Pten is the most frequently mutated gene
in human cancers, and is inactivated by a variety of mechanisms in some leukemias.127,128
It was well documented that conditional deletion of Pten tumor suppressor gene in bone marrow
HSCs causes their short-term expansion, whereas long-term decline leads to enhanced level of
HSC activation. Pten-deficient HSCs engraft normally in recipient mice, but have an impaired
ability to sustain hematopoietic reconstitution, reflecting the dysregulation of their cell cycle
and decreased retention in the bone marrow niche. Pten deficiency has no discernable effect
on HSCs differentiation or survival; however, after 3 weeks of Pten deletion, HSCs became
depleted. Thus, Pten has essential roles in restricting the activation of HSCs, in lineage fate
determination and in the prevention of leukemogenesis.128,129
In contrast to this requirement for Pten in maintenance of HSCs, LSCs arose and expanded in
number after Pten deletion. The LSCs were transplantable and could be enriched among cells
that expressed HSC markers. Most mice died with AML and ALL within 6 weeks of Pten
deletion.128,129
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It was demonstrated that Pten deletion in prostate epithelium progenitor cells led to senescence
response by a p53-mediated mechanism.129-131 An analogous mechanism could explain the
response of HSCs after Pten deletion; moreover, mutations that occur during the progression
of Pten-deficient cells to leukemia, such as p53, could bypass the senescence response in LSCs.
Further investigations could elucidate whether Pten deletion in HSCs induces a senescence
response and whether the p53 pathway might be involved in this mechanism.
Pten deletion leads to increased activation of Akt and mTOR. Administration of rapamycin, a
potent and specific inhibitor of mTOR, to Pten-deleted mice eliminate LSCs and maintain the
health of mice, but it also rescued the depletion of Pten-deficient HSCs. Pten-deficient HSCs
could provide long-term multilineage reconstitution of irradiated mice as long as the mice
continued to be treated with rapamycin. This demonstrates that many effect of Pten deletion
were mediated by increased mTOR activation. Therefore, LSCs could be eliminated by
targeting mTOR without compromising normal stem cells.
Using a murine lymphoma model, Lowe and co-workers131 demonstrated that Akt promotes
tumorigenesis and drug resistance by disrupting apoptosis and that disruption of Akt signaling
using the mTOR inhibitor rapamycin reverses chemoresistance in lymphomas expressing Akt,
but not in those tumors in which the apoptotic machinery is compromised. Treatment of these
mice with doxorubicin (a DNA-intercalating agent), together with rapamycin, resulted in a
strong tumor remission, lasting more than 60 days.131 Moreover, further evidence suggests
that the transcription factor NF-κB functions as an important tumor survival factor by
conferring rapamycin resistance and that concomitant inhibition of NF-κB and mTOR
increases cancer cells death.132 Therefore, rapamycin and its analogues may also result in
synergistic interactions with other agents.
These results provide further in vivo validation for a strategy to reverse drug resistance in human
cancers, such as leukemia, and highlight the potential role of translational deregulation in
oncogenesis, resistance and LSCs, shedding light on the importance of cancer therapy based
on tumor genotype.
Targeting leukemia stem cells by inhibition the Raf/MEK/ERK pathway
Another well-studied pathway is the Raf/MEK/ERK kinase cascade. It is overexpressed in over
70% of cases of AML.133 Drugs that target proteins in this pathway are currently being
extensively studied with the belief that targeting one point of this pathway will have
monumental effects on the entire pathway and its numerous downstream targets. Small-
molecule weight inhibitors, which target Ras, Raf and MEK, have been developed and recently
reviewed in Leukemia.111 Additional drugs such as coumermyicin, which prevents the
dimerization of Raf, thus suppressing its activity, may eventually be examined in leukemia
therapy.134
Although Raf/MEK/ERK and PI3K/Akt/mTOR are two seemingly separate pathways, their
interaction or cross-talk is of intense interest. This cross-talk first became evident when cells
treated with a PI3K inhibitor were also found to have decreased levels of ERK.135 It has been
further backed by numerous studies documenting the interactions between PI3K and Akt and
various isoforms of Raf.136 However, in other cell types, there is suppression of Akt, resulting
in enhanced activation of ERK. In addition, inhibitors of ERK also suppressed p70S6K
phosphorylation, a protein downstream of mTOR heavily implicated in its effect on protein
synthesis. Indeed both the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways interact to
regulate p70S6K activation. The BCR-ABL oncoprotein, critical for CML, is usually
effectively inhibited by the drug imatinib. However, in some cases resistance to imatinib
occurs. Thus, studies combining imatinib with inhibitors targeting portions of either of these
two signaling pathways are showing promise in combating this resistance.137
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Conclusions
In summary, the specific therapeutic targeting of the LSC is a field in its infancy. The tumor
cell microenvironment or niche may also be an important therapeutic target, and Rac inhibitors
as well as various anti-integrin antibodies may be appropriate.138,139 As we learn more about
the various LSCs, it undoubtedly will result in novel ways to treat leukemias. Stem cells pose
challenges to classical chemotherapeutic approaches owing to their slow rate of proliferation
and quiescent-like properties. In additionally, the increased expression of ABC transporter
proteins and various cell-signaling pathways further adds complexity to the situation. However,
their pivotal role in the overall control and propagation of a variety of cancers and some initial
responses to various inhibitors and treatments shows their therapeutic potential. Ultimately,
previous research has shown that we must be clever and multifaceted in our approach to design
therapies, which may be effective in selectively eliminating these cancer-initiating cells.
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Figure 1.
Overview of normal HSCs and LSCs. LSCs originate from HSCs after various complex genetic
mutations. The normal HSC differentiates into functional cells of the lymphoid and myeloid
lineages, which perform their biological functions and normally die by apoptosis after an
appropriate time period. In contrast, LSCs acquire mutations that allow them to grow and
persist in the presence of chemotherapeutic drugs, whereas the majority of the leukemic cells
that arise after mutation are unable to continue to proliferate after chemotherapy.
Understanding the difference between the LSC and the majority of leukemia that are not LSC
may allow the generation of more effective therapeutic strategies. The spiral shading in the
HSC, LSC and leukemia cells indicates their ability to propagate indefinitely. The circular
arrow indicates self-renewal.
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Figure 2.
Comparison of LSC and leukemic cells. Although both LSC and leukemic cells originate from
HSC, they display distinct differences in terms of cell cycle status and drug transporter activity,
which may be responsible for the difference in susceptibility to chemotherapeutic approaches.
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Figure 3.
Phenotypic difference between AML LSC and AMLs. The bulk of leukemic AMLs differ from
AML stem cells in the expression of CD38+ and other genes. This figure is a simplification as
some AML (e.g., AML FAB M3; APL) are CD34-. Functionally, these two types of cells also
differ in their ability to repopulate NOD-SCID mice. NOD-SCID, non-obese diabetic-severe
combined immunodeficient.
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Figure 4.
Phenotypic differences between CML LSC and CMLs. Although both CML-stem cells and
the CML cells contain the BCR-ABL chromosomal translocation, they differ in their
proliferative capacity in the presence of certain BCR-ABL inhibitors. This may be due to the
presence of certain pre-existing mutations in the BCR-ABL gene in the CML-LSCs. In
addition, the CML-LSCs display differences in cytokine expression (IL-3, G-CSF), which may
promote autocrine proliferation. The CML-LSC also displayed elevated transporter, Oct-1 and
β-catenin pathway expression, which may result in altered proliferation in comparison with
CML cells.
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Figure 5.
Overview of Wnt/β-catenin signaling pathway in leukemia. The Wnt signaling pathway is a
central pathway, which results in the transmission of growth-promoting signals that control
the activity of β-catenin. Stabilization of β-catenin results in its translocation to the nucleus
and promotion of gene transcription by TCF/LEF transcription complex. This can result in the
transcription of genes such as Cyclin D, c-Myc, SALL-4, PPARδ and other genes. In the
absence of Wnt binding of Frizzled, the multiprotein destruction complex (MDC) is activated
and glycogen synthase kinase 3β (GSK-3β) phosphorylates β-catenin and it is targeted for
proteasomal degradation. In the presence of Wnt binding, this complex is inactivated.
Interactions with other signaling pathways such as PI3K/PTEN/Akt exist, which influence
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GSK-3β activity (inactivation). This pathway can be activated by Flt-3 and other receptors.
Thus, there are interactions between the Wnt and PI3K/PTEN/Akt pathways. Wnt is also
postulated to interact with the Notch and other signaling pathways. The Wnt pathway is
frequently dysregulated in leukemia. This can occur by mutations at Flt-3, chromosomal
translocations, methylation of the promoter regions inhibitory genes such as WIF-1 and many
other mechanisms (e.g., mutations at either PI3K or PTEN, which result in the activation of
Akt expression).
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Figure 6.
Targeting the AML-LSC. Potential targets on the AML-LSC are indicated. In general, these
targets are not expressed or are expressed at different levels in the AML.
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Figure 7.
Sites of interaction of signal transduction pathway inhibitors. Various types of inhibitors have
been developed to target different molecules involved in signal transduction.
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